US states, FTC accuse Martin Shkreli of violating lifetime drug industry ban

New York and six other state attorneys general joined the FTC in alleging Martin Shkreli repeatedly breached his lifetime ban from the pharmaceutical industry. The action follows his 2022 conviction and lifetime ban for antitrust violations related to Daraprim price gouging. This escalates legal enforcement against Shkreli, potentially leading to further penalties or contempt proceedings.